Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

By Steve Cummings, J. San Martin, M. McClung, E. Siris, Richard Eastell, I. Reid, P. Delmas, H. Zoog, M. Austin, Andrea Wang and 6 more. New England Journal of Medicine, 2009

2,981 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Orthopedics and Sports Medicine

View Paper: https://www.semanticscholar.org/paper/90c6008b8e9c20ab2369b0535da723102d0a289f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Oncology

In Orthopedics and Sports Medicine

Citations in the corpus

Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014, background): “by about 40 %, and nonvertebral fractures by about 20 % over 3 years [56].”
The clinician’s guide to prevention and treatment of osteoporosis (2022, background): “Denosumab reduces incidence of vertebral fractures by about 68% at 1 year, hip fractures by about 40% and non-vertebral fractures by about 20% at 3 years, with continued fracture reduction in studies extended to 5 years [160, 185, 186].”
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary (2010, background): “Denosumab may increase the risk of cellulitis.(43) Raloxifene and hormone therapy increase the risk of thromboembolic events, including pulmonary embolism.”
Calcific aortic stenosis: a disease of the valve and the myocardium. (2012, background): “Increased expression of RANKL and reduced levels of OPG have been observed in osteoporosis and have led to the development the anti-RANKL monoclonal antibody denosumab as a highly efficacious and well-tolerated osteoporosis treatment (101).”
Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo‐Controlled FREEDOM Trial and Its Extension (2018, background): “ized study of denosumab in postmenopausal women with osteoporosis, denosumab given subcutaneously (sc) once every 6months (Q6M) for 3 years reduced the risk of vertebral fractures detected on radiographs by 68%, along with significant reductions in nonvertebral and hip fractures.((1)) The low rates ”
Estrogen and the Skeleton (2012, positive): “Other drugs that inhibit bone resorption, such as bisphosphonates (20) or an antibody to RANKL (21) lead to similar decreases in bone formation.”
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. (2010, background): “In a large trial of women with postmenopausal osteoporosis, denosumab resulted in significant reductions in the incidence of vertebral, nonvertebral, and hip fractures.(19) Two phase II trials of patients with bone metastases further demonstrated that denosumab, at doses ranging from 30 to 180 mg ad”